Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections

Clin Infect Dis. 2020 Jul 27;71(3):667-671. doi: 10.1093/cid/ciz1131.

Abstract

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

Keywords: KPC; meropenem; porin; resistance; vaborbactam.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins
  • Boronic Acids
  • Carbapenem-Resistant Enterobacteriaceae*
  • Enterobacteriaceae Infections* / drug therapy
  • Humans
  • Klebsiella pneumoniae / genetics
  • Meropenem / therapeutic use
  • Microbial Sensitivity Tests
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Boronic Acids
  • vaborbactam
  • beta-Lactamases
  • Meropenem